Table 1.
CAR-T cell therapies currently on the market.
| Name | Target | Manufacturer | Indication | Price/needle | Country | First approval | Carrier |
|---|---|---|---|---|---|---|---|
| Kymriah (tisagenlecleucel) |
CD19 | Novartis Pharmaceuticals Corporation | Relapsed or refractory follicular lymphoma | 47.5 thousand dollars | USA(2017)/EU(2018)/Cananda(2019)/Janpan(2019) | 2017-09-30 | Lentivirus |
| Yescarta (axicabtagene ciloleucel) |
CD19 | Kite Pharma Inc. | Large B-cell lymphoma | 37.5 thousand dollars | USA(2017)/EU(2018)/Cananda(2019) | 2017-10-18 | Retrovirus |
| Tecartus (brexucabtagene autoleucel) |
CD19 | Kite Pharma, Inc. | Relapsed or refractory mantle cell lymphoma, relapsed or refractory (r/r) B-cell, precursor acute lymphoblastic leukemia | 37.3 thousand dollars | USA(2020)/EU(2020) | 2020-10-28 | Retrovirus |
| Breyanzi (lisocabtagene maraleucel) |
CD19 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Large B-cell lymphoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B | 41.03 thousand dollars | USA(2021) | 2021-02-05 | Lentivirus |
| Abecma (idecabtagene vicleucel) |
BCMA | Celgene Corporation, a Bristol-Myers Squibb Company | Relapsed or refractory multiple myeloma | 43.7968 thousand dollars | USA(2021) | 2021-03-26 | Lentivirus |
| Yescarta (AxicabtageneCiloleucel) | CD19 | Fosunkitebio. | Relapsed or refractory (r/r) B-cell | 1.2 million RMB | CN(2021) | 2021-06-22 | Retrovirus |
| Relma-cel (Relmacabtagene autoleucel) | CD19 | JW (Cayman) Therapeutics Co. Ltd | Relapsed or refractory (r/r) B-cell | Unknown | CN(2021) | 2021-09-03 | Unknown |